Emerging treatment options for recurrent ovarian cancer: The potential role of olaparib

Abstract

Olaparib has shown promising anticancer activity as a single agent in the treatment and maintenance of recurrent ovarian cancer in early clinical trials, but it is far from standard therapy. This article outlines the problem of relapsed ovarian cancer and the mechanisms of poly(ADP-ribose) polymerase inhibitors and reviews the recent literature pertaining to olaparib in ovarian cancer. © 2013 Shaw and Hall, publisher and licensee Dove Medical Press Ltd.